ARTICLE | Clinical News
Turning Point sinks on ASCO update for repotrectinib
May 31, 2019 10:07 PM UTC
Updated data showing a lower response rate in a cohort of ROS1-positive NSCLC patients treated with repotrectinib than a previous analysis sent shares of Turning Point tumbling on the first day of the American Society of Clinical Oncology meeting in Chicago.
The updated data came just weeks after Turning Point Therapeutics Inc. (NASDAQ:TPTX) debuted on NASDAQ with a $166.5 million IPO...